Skip to main content
. 2021 Mar 1;14(3):338–347.

Table 2.

Intergroup distributions of ages, existence of bone metastasis, type of breast cancer, localization of breast cancer, tumor diameter by category, number of axillary lymph nodes, existence of estrogen and progestrone receptors, and HER2 protein

Characteristic N (%)
Groups of Age
    < 30 3 (0.3)
    30-39 112 (10.2)
    40-49 312 (28.4)
    50-59 271 (24.6)
    > 60 402 (36.5)
Bone Metastasis
    (+) 174 (15.8)
    (-) 926 (84.2)
CA Type
    Invasive Ductal Carcinoma (IDC) 926 (84.2)
    Invasive Lobular (IL) & Ductal Carcinoma (DC) 90 (8.2)
    Invasive Lobular Carcinoma (ILC) 63 (5.7)
    Phyllodes 1 (0.1)
    Tubular Carcinoma 16 (1.5)
    Metaplastic Carcinoma 4 (0.4)
CA Localization
    Left Upper Outer 297 (27.0)
    Left Upper Inner 93 (8.4)
    Left Lower Outer 81 (7.2)
    Left Lower Inner 76 (6.9)
    Right Upper Outer 269 (24.4)
    Right Upper Inner 68 (6.2)
    Right Lower Outer 86 (7.8)
    Right Lower Inner 55 (5.0)
    Left Central     3 (0.3)
    Left Retroareolar 34 (3.1)
    Right Retroareolar 38 (3.5)
Tumor Diameter
    < 1 cm     101 (9.2)
    1-1.99 cm 357 (32.4)
    2-2.99 cm 322 (29.3)
    > 3 cm 320 (29.1)
Num. of Axillary Lymph Nodes
    0 576 (52.4)
    1-3 306 (27.8)
    ≥ 4 218 (19.8)
Estrogen Receptor (ER)
    Positive 906 (82.4)
    Negative 194 (17.6)
Progesterone Receptor (PgR)
    Positive 811 (73.7)
    Negative 289 (26.3)
HER2
    Positive 170 (15.5)
    Negative 826 (75.1)
    Indefinite Positive     104 (9.5)
HER2 Score
    (-) 662 (60.2)
    (+) 165 (15.0)
    (++) 119 (10.8)
    (+++) 154 (14.0)

N: Number; CA: Cancer; HER2: Human Epidermal Growth Factor Receptor 2.